A treatment algorithm based on high-flow nasal cannula oxygen therapy reduces short-term mortality of people with idiopathic pulmonary fibrosis who develop acute respiratory failure, a study says. The findings of the study, “High-flow nasal cannula oxygen therapy to treat acute respiratory failure in patients with acute exacerbation…
Europe’s umbrella organization for 800 rare disease associations has developed a sweeping initiative to help the continent’s 30 million rare disease patients and their caregivers learn about their conditions, find assistance and receive treatment. Eurordis-Rare Diseases Europe hopes to improve the current piecemeal treatment and support program with a holistic,…
Treatment with Esbriet (pirfenidone) slows the worsening of breathlessness in patients with more severe idiopathic pulmonary fibrosis (IPF), a post-hoc analysis of the ASCEND and CAPACITY trials shows. The study, “Effect of pirfenidone on breathlessness in patients with idiopathic pulmonary fibrosis,” was published in the European…
Note: This is the second article in a three-part series written in collaboration with respiratory therapist Mark W. Mangus Sr., RRT, RPFT, FAARC, and oxygen expert Ryan Diesem. The first part can be found here. When it comes to home improvement, people typically want three things from a contractor:…
The presence of auto-antibodies (self-directed antibodies) known as antineutrophil cytoplasmic antibodies do not correlate with disease severity or survival in North American patients with idiopathic pulmonary fibrosis (IPF), according to a new study. The study, “Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in North American Patients with…
People with rare diseases know that the right government policies can make a big difference in the quality of their own lives, and those of their caregivers. But most lawmakers aren’t experts in even one well-known disease — let alone the world’s estimated 7,000 rare disorders. So how does the…
Key pharmaceutical and academic leaders in idiopathic pulmonary fibrosis (IPF) will gather at the Third Annual IPF Summit in San Diego to discuss the latest developments in the field. The conference, taking place Aug. 27-29, aims to create a discussion and networking environment to overcome the translational gap…
The use of oxygen at rest is associated with a greater likelihood of death or lung transplant in people with idiopathic pulmonary fibrosis (IPF), a study shows. The results also showed that lower lung function at the start of the study, as measured by tests like forced vital…
Increased levels of specific proteins found in blood, namely C-reactive protein, lactate dehydrogenase, and total cholesterol, may predict the risk of mortality after acute exacerbation in idiopathic pulmonary fibrosis (IPF) patients, according to a retrospective study performed in Japan. The study, “Possible Serological Markers to Predict…
Lung Therapeutics announced that it has raised $36 million in Series C financing to fund two projects, including a healthy volunteer Phase 1 clinical trial testing LTI-03, an experimental therapy for idiopathic pulmonary fibrosis (IPF). Currently approved therapies for IPF can slow disease progression, but cannot restore…
Get regular updates to your inbox.
